Publication:
Immunotherapy for lung cancer

Thumbnail Image

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Karadurmuş,N.
Akyürek,N.
Aydiner,A.
Savaş,R.
Sönmez,Ö.
Şendur,M.A.N.
Oyan,B.
Yalman,D.
Yilmaz,M.U.
Yilmaz,Ü.

Publication Date

Language

Type

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Lung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death re-ceptor-1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 anti-bodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics.

Source

Publisher

Turkiye Klinikleri

Subject

Immunotherapy, Non small cell lung cancer, Immune checkpoint inhibitor

Citation

Has Part

Source

Journal of Oncological Science

Book Series Title

Edition

DOI

10.37047/jos.2022-92712

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

4

Views

4

Downloads

View PlumX Details